Fig. 5.
The effect of SCH58261 on cardiac ROS production. (A) Kinetic measurement of NADPH-dependent O2•− production detected by lucigenin chemiluminescence in cardiac homogenates from wild-type mice treated in vivo with vehicle or SCH58261 (3 mg/kg body weight). Tiron (an O2•− scavenger) and apocynin (an NADPH oxidase inhibitor) were used to confirm the specificity of the assay. (B) Difference in NADPH-dependent O2•− production between heart homogenates from vehicle-treated (0 mg of SCH58261) and SCH58261 (3 and 10 mg/kg body weight)-treated mice. n=12 animals/per group. (C) The effect of SCH58261 on ROS production by cultured H9C2 cardiac myocytes. The cell homogenate from 2×106 cells was used for each measurement. n=3 independent cell cultures. MLU: mean light unit of 15 measurements. *P<0.05 for indicated values versus control value (0 mg SCH58261).